Clinical Trial Update: Endostar Combined With Concurrent Chemoradiotherapy for Locoregionally Advanced Nasopharyngeal Carcinoma [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating Endostar in combination with concurrent chemoradiotherapy for locoregionally advanced nasopharyngeal carcinoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Nasopharyngeal Carcinoma

Drugs mentioned

• Endostar (recombinant human endostatin)

Snippet

Sponsor: First Affiliated Hospital of Guangxi Medical University | Conditions: Nasopharyngeal Carcinoma | Phase 3 | Status: UNKNOWN